PULM — Pulmatrix Inc

Pulmatrix Inc (PULM) is a biotechnology company listed on NASDAQ. It is led by Peter Ludlum CMA, MBA, based in 945 Concord Street, Framingham, MA, United States, 01701, with about 2 employees. Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Net income was -$877.0K. PULM currently screens at market cap $5.4M.

Use this PULM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PULM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PULM SEC filings page. Lician reads the product cache first so this HTML stays unique to Pulmatrix Inc even when a live quote feed is slow.